Tauns Laboratories, Inc. (197A) Stock Statistics & Valuation Metrics

Tauns Laboratories, Inc. has a market cap or net worth of ¥54.95B. The enterprise value is ¥68.05K.

Tauns Laboratories, Inc. has 106,702,350 shares outstanding. The number of shares has decreased by -2.65% in one year.

Tauns Laboratories, Inc.’s return on equity (ROE) is 0.28 and return on invested capital (ROIC) is 6.86%.

The current PE Ratio of Tauns Laboratories, Inc. is 9.8. Tauns Laboratories, Inc.’s PEG ratio is -0.57.

In the last 12 months, Tauns Laboratories, Inc. had revenue of 14.37B and earned 5.50B in profits. Earnings per share was 52.28.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Tauns Laboratories, Inc. pays an annual dividend of ¥14.5, resulting in a dividend yield of 5.47%

Tauns Laboratories, Inc. upcoming earnings date is Nov 12, 2026, TBA (Confirmed).

Tauns Laboratories, Inc. as a current ratio of 1.26, with Debt / Equity ratio of 109.47%

In the past 12 months, Tauns Laboratories, Inc. has paid 2.40B in taxes.

Tauns Laboratories, Inc. EV to EBITDA ratio is 12.64, with an EV/FCF ratio of -10.18.

Tauns Laboratories, Inc. has ¥3.56B in cash and marketable securities with ¥21.26B in debt, giving a net cash position of -¥17.70B billion.

Gross margin is 61.39%, with operating margin of 29.23%, and net profit margin of 38.24%.

The average price target for Tauns Laboratories, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―